Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00449748 · ClinicalTrials.gov registry record · Phase 2
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00449748: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00449748 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00449748, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.
Primary Outcome
Efficacy reported as objective response. Objective response defined as change in serum tryptase level or bone marrow mast cell percentage.
Interventions
- DRUG RAD001 (Everolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
What the finished NCT00449748 record still lists
NCT00449748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which RAD001 (Everolimus) is the first listed.
NCT00449748 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00449748 about?
NCT00449748 is a clinical study titled "Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis". The goal of this clinical research study is to see if RAD001 can help to control the disease in patients with systemic mastocytosis (SM). The safety of this treatment will also be studied.
What is the current status of trial NCT00449748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00449748?
The interventions under investigation include: RAD001 (Everolimus) (DRUG).
Who is sponsoring clinical trial NCT00449748?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00449748's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia